Such defects in cell-autonomous immunity commonly arise in the context of the immune editing of tumors, as reductions in the abilities of cancer cells to induce, secrete, or respond to interferon (IFN) may facilitate their evasion from the selective pressures applied by anti-tumor immunity [27,28,29,30,31]. This evidence concerns the gene IFNA1 and cancer.